OR WAIT 15 SECS
Innovate UK has awarded Epsilogen with further grant funding for the development of the next generation antibody treatments for ovarian cancer.
The United Kingdom’s innovation company, Innovate UK, has awarded Epsilogen with further grant funding, worth £0.5 million (US $0.6 million), for the development of the next generation antibody treatments for ovarian cancer.
Epsilogen, a developer of novel immunoglobulin E (IgE) antibodies to treat cancer, announced the extra funding in a July 20, 2020 press release, and stated that the monies would be used to further develop the proprietary IGEG platform. According to the company, IGEG antibodies combine key structural elements of both IgE and IgG antibodies into a novel and proprietary antibody structure. Therefore, the IGEG antibody molecule is able to bind to both IgE and IgG receptors.
The company’s first antibody to enter clinical trials is Mov18 IgE, which is currently in a Phase I study involving cancer patients with advanced solid tumors, principally ovarian. Interim results from the trial support the safety and potential efficacy of an IgE antibody as a treatment for advanced cancer.
“Epsilogen is a pioneer in the use of IgE antibodies and engineered IgE derivatives to treat cancer. We are very pleased to have been awarded our third grant from Innovate UK,” said Dr. Tim Wilson, CEO of Epsilogen, in the press release. “Our goal is to harness the potency of the IgE-mediated immune response and thereby provide patients with new safe and effective treatment options for these serious diseases.”